Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,764 across all filing types
Latest filing 2023-10-23 Investor Presentation
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) dated 23rd October 2023, enclosing a presentation to analysts on unaudited consolidated financial results for the quarter and half year ended 30th September 2023. The content includes revenue summaries and financial highlights for Q2 FY 2023-24. The document is relatively short (2037 characters) and explicitly states it is a presentation to analysts. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. It is not a full financial report (like an Interim Report) nor an earnings release (which would be a brief announcement). Therefore, the correct classification is Investor Presentation (IP).
2023-10-23 English
Investor presentation
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding a presentation to analysts on unaudited consolidated financial results for the quarter and half year ended 30th September 2023. It includes summary revenue data for Q2 FY 2023-24. The document is a presentation of financial results to analysts, not the full financial report itself. It is not an earnings release (which is typically a brief announcement), nor is it a full interim report. The document is a presentation to investors/analysts focusing on financials and market position. Therefore, it fits the category of Investor Presentation (IP). The document length is 2037 characters, which is consistent with a presentation rather than a full report or announcement of report publication.
2023-10-23 English
Financial results for quarter and half year ended 30-sep-23
Interim / Quarterly Report Classification · 95% confidence The document is a detailed filing from Torrent Pharmaceuticals Limited dated 23rd October 2023. It includes an independent auditor's report on the standalone quarterly financial results for the quarter and half year ended 30th September 2023. The report contains the auditor's opinion, basis for opinion, management and board responsibilities, and auditor responsibilities, which are typical components of an audit report. The document also includes detailed financial data such as income, expenses, and other financial metrics for the quarter and half year periods. The presence of the audit report and detailed financial results indicates this is not merely an announcement or a press release but the actual audited financial results document. The document references compliance with SEBI Listing Regulations and Indian Accounting Standards, further confirming it is a formal financial report. Given the content and length (15,000 characters), it is a comprehensive financial report for a period shorter than a full fiscal year (quarter and half year), which fits the definition of an Interim / Quarterly Report (IR).
2023-10-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) announcing a post quarterly financial result conference call scheduled for October 23, 2023, to discuss the financial performance for the quarter and half year ended September 30, 2023. It provides dial-in details for the call but does not contain any financial data or analysis itself. The document length is short (2185 characters) and it is clearly an announcement of an event related to the quarterly results, not the results or report itself. Therefore, it fits the category of a Call Transcript announcement or invitation. Since it is announcing the conference call rather than providing the transcript, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the call. However, given the specific nature of the announcement about the conference call for quarterly results, the most precise classification is Call Transcript (CT) as it relates directly to the earnings call event. Confidence is high due to clear keywords and context.
2023-10-16 English
Post Quarterly Financial Result Conference Call with Investors / Analyst
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) announcing a post quarterly financial result conference call scheduled for 23rd October 2023 to discuss the financial performance for the quarter and half year ended 30th September 2023. It provides dial-in details for the call but does not contain any financial data or analysis itself. The document length is short (2185 characters) and it is clearly an announcement of an event related to quarterly results, not the results or report itself. According to the classification rules, such announcements of conference calls are best classified as Call Transcript (CT) only if the full transcript is provided. Since this is only an announcement of the call, it does not fit CT. It is also not a report or earnings release. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the conference call event.
2023-10-16 English
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is an official communication from Torrent Pharmaceuticals Limited to stock exchanges (BSE and NSE) regarding the loss of share certificates by certain shareholders. It includes details of the lost certificates and requests to trading members to refrain from trading these shares. The document also contains letters from the Registrar and Transfer Agent (RTA), KFin Technologies Limited, acknowledging receipt of requests for duplicate share certificates. There is no financial data, no discussion of financial results, no management commentary, no voting results, no legal proceedings, or other report types. The content is a regulatory announcement related to share certificate loss and administrative handling of duplicate certificates. This fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories.
2023-10-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.